Tevimbra is an immune checkpoint inhibitor (PD-1 blocker) used to treat unresectable or metastatic esophageal squamous cell carcinoma (ESCC) after prior systemic chemotherapy without PD-(L)1 inhibitors.
Mechanism of Action:
Blocks PD-1 on T-cells, preventing cancer cells from evading immune detection.
Enhances T-cell-mediated tumor destruction.
Dosage & Administration:
200 mg IV infusion every 3 weeks until disease progression or intolerable toxicity.
First infusion: Administer over 60 minutes.
Subsequent infusions (if tolerated): May reduce to 30 minutes.
Patient Education Before Administration
Pre-Infusion Assessment:
Verify allergies, medical history (autoimmune disorders, organ transplants, pregnancy).
Confirm pregnancy status (avoid pregnancy for ≥4 months post-treatment).
Review concurrent medications (risk of immune-mediated interactions).
Infusion Preparation:
Inspect solution: Should be clear to slightly opalescent, colorless to pale yellow.
Patient Instructions:
Wear comfortable clothing (easy IV access).
Hydrate well before the appointment.
Arrange transportation (fatigue/dizziness may occur post-infusion).
Administration Guidelines
IV Setup:
Use 0.9% NaCl or 5% dextrose as diluent if needed.
Administer via IV line with a 0.2–5 micron filter.
Infusion Monitoring:
First dose: Monitor for hypersensitivity reactions (flushing, dyspnea, rash).
Vital signs: Check before, during, and after infusion.
Rate Adjustments:
If mild reaction (Grade 1-2): Pause infusion, manage symptoms, resume at slower rate.
If severe reaction (Grade 3-4):Stop infusion permanently.
Kevin Van, PharmD, BCPS (Editor)
Kevin Van, PharmD, BCPS (Editor)